BACKGROUND: Brain-derived neurotrophic factor (BDNF), tyrosine kinase receptor (trkB-TK+) and glutamic acid decarboxylase (GAD67) mRNA levels have previously been found to be reduced in the prefrontal cortex of patients with schizophrenia. To determine whether this reduction extends to other brain regions, we measured the expression levels of BDNF, trkB-TK+ and GAD67 mRNA in regions of the hippocampus, including the dentate gyrus (DG), cornu ammonis subfields (CA1-4), subiculum and entorhinal cortex (EC) of individuals with schizophrenia, bipolar disorder, major depression and unaffected controls. METHODS: In situ hybridization was performed on postmortem brain tissue obtained from the Stanley Foundation Consortium and analyzed using film-based quantification. RESULTS: Analyses of covariance comparing the expression of mRNA among all groups revealed a significant decrease in BDNF mRNA in CA4 in the bipolar disorder group compared with controls (33%). We found trkB-TK+ mRNA levels to be significantly reduced in CA4 in the schizophrenia group (36%) and in layer II of the EC in the bipolar disorder and major depression groups (28%, 21%, respectively) compared with controls. In addition, GAD67 mRNA levels were reduced in patients with schizophrenia in both the DG (23%) and CA4 (60%) compared with controls. Individuals with major depression also expressed significantly less GAD67 mRNA (44%) compared with controls in CA4 of the hippocampus. LIMITATIONS: It is necessary to account for factors that influence the molecular preservation in postmortem brain tissue, including pH, postmortem interval and tissue storage time. Moreover, there are limitations to the sensitivity of the film-based method of quantification. CONCLUSION: Our findings show abnormal BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders, indicating that fundamental properties of hippocampal signalling transmission, plasticity and circuitry may be affected in individuals with these major mental illnesses.
BACKGROUND:Brain-derived neurotrophic factor (BDNF), tyrosine kinase receptor (trkB-TK+) and glutamic acid decarboxylase (GAD67) mRNA levels have previously been found to be reduced in the prefrontal cortex of patients with schizophrenia. To determine whether this reduction extends to other brain regions, we measured the expression levels of BDNF, trkB-TK+ and GAD67 mRNA in regions of the hippocampus, including the dentate gyrus (DG), cornu ammonis subfields (CA1-4), subiculum and entorhinal cortex (EC) of individuals with schizophrenia, bipolar disorder, major depression and unaffected controls. METHODS: In situ hybridization was performed on postmortem brain tissue obtained from the Stanley Foundation Consortium and analyzed using film-based quantification. RESULTS: Analyses of covariance comparing the expression of mRNA among all groups revealed a significant decrease in BDNF mRNA in CA4 in the bipolar disorder group compared with controls (33%). We found trkB-TK+ mRNA levels to be significantly reduced in CA4 in the schizophrenia group (36%) and in layer II of the EC in the bipolar disorder and major depression groups (28%, 21%, respectively) compared with controls. In addition, GAD67 mRNA levels were reduced in patients with schizophrenia in both the DG (23%) and CA4 (60%) compared with controls. Individuals with major depression also expressed significantly less GAD67 mRNA (44%) compared with controls in CA4 of the hippocampus. LIMITATIONS: It is necessary to account for factors that influence the molecular preservation in postmortem brain tissue, including pH, postmortem interval and tissue storage time. Moreover, there are limitations to the sensitivity of the film-based method of quantification. CONCLUSION: Our findings show abnormal BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders, indicating that fundamental properties of hippocampal signalling transmission, plasticity and circuitry may be affected in individuals with these major mental illnesses.
Authors: Francine M Benes; Benjamin Lim; David Matzilevich; Sivan Subburaju; John P Walsh Journal: Proc Natl Acad Sci U S A Date: 2008-12-22 Impact factor: 11.205
Authors: Heather C Strasser; Jessica Lilyestrom; Ebony R Ashby; Nancy A Honeycutt; David J Schretlen; Ann E Pulver; Ramona O Hopkins; J Raymond Depaulo; James B Potash; Barbara Schweizer; Khara O Yates; Elizabeth Kurian; Patrick E Barta; Godfrey D Pearlson Journal: Biol Psychiatry Date: 2005-03-15 Impact factor: 13.382
Authors: Anthony P Weiss; Daniel L Schacter; Donald C Goff; Scott L Rauch; Nathaniel M Alpert; Alan J Fischman; Stephan Heckers Journal: Biol Psychiatry Date: 2003-01-01 Impact factor: 13.382
Authors: R E Gur; P D Mozley; S M Resnick; L H Mozley; D L Shtasel; F Gallacher; S E Arnold; J S Karp; A Alavi; M Reivich Journal: Arch Gen Psychiatry Date: 1995-08
Authors: Courtney S Jernigan; Dharmendra B Goswami; Mark C Austin; Abiye H Iyo; Agata Chandran; Craig A Stockmeier; Beata Karolewicz Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2011-05-23 Impact factor: 5.067
Authors: Devon B Oskvig; Abdel G Elkahloun; Kory R Johnson; Terry M Phillips; Miles Herkenham Journal: Brain Behav Immun Date: 2012-01-30 Impact factor: 7.217
Authors: Basira Salehi; Nora Preuss; Jan Willem van der Veen; Jun Shen; Alexander Neumeister; Wayne C Drevets; Colin Hodgkinson; David Goldman; Jens R Wendland; Andrew Singleton; Jesse R Gibbs; Mark R Cookson; Gregor Hasler Journal: Int J Neuropsychopharmacol Date: 2012-12-20 Impact factor: 5.176